Pertuzumab (P) with trastuzumab (T) and chemotherapy (CTX) in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer: An international phase III study (JACOB).
Josep Tabernero
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; ImClone Systems; Lilly; Merck KGaA
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Paulo Marcelo Hoff
Consultant or Advisory Role - GlaxoSmithKline (U); Roche (U)
Research Funding - AstraZeneca; GlaxoSmithKline; Roche
Lin Shen
Consultant or Advisory Role - Roche
Research Funding - Roche
Atsushi Ohtsu
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Ron Yu
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Roche
Jennifer Eng-Wong
Employment or Leadership Position - Genentech/Roche
Stock Ownership - Genentech/Roche
Yoon-Koo Kang
Consultant or Advisory Role - Novartis; Roche; Sanofi
Honoraria - Novartis; Roche; Sanofi
Research Funding - Novartis; Roche; Sanofi